News
-
-
PRESS RELEASE
A Novel Broad-Spectrum Antiviral Against Influenza A Viruses, NV-387, Could Be an Important Weapon to Fight Bird Flu H5N1, Says NanoViricides
NanoViricides, Inc. comments on the potential of ultra-broad-spectrum antiviral NV-387 against bird flu H5N1 viruses. The company's drug candidate shows promising results in lethal animal model studies -
-
PRESS RELEASE
A Novel Broad-Spectrum Antiviral Against Influenza A Viruses, NV-387, Is Effective in Protecting Lungs from Damage in Lethally Infected Animal Model
NanoViricides, Inc. reports positive results of NV-387 in protecting lungs from damage in influenza virus infection. NV-387 treatment showed reduced lung infiltration, cell death, mucus load, and increased survival -
-
PRESS RELEASE
Orally Administered NV-387 Results in Ideal Flat Blood Concentration Profile for Sustained Antiviral Effect
NanoViricides, Inc. reports positive results of broad-spectrum antiviral drug NV-387 in animal models, showing sustained antiviral effect with extended flat blood concentration profile upon oral administration -
-
PRESS RELEASE
The Sustained, Slow Declining, Blood Concentration Profile of NV-387 Enables Infrequent Dosing for Strong Antiviral Effect
NanoViricides, Inc. reports positive pharmacokinetic profile of NV-387 in non-human primate model, showcasing sustained blood concentrations enabling less frequent dosing for its broad-spectrum antiviral agent. The unique polymeric design supports potential against RSV, COVID, and influenza -
-
PRESS RELEASE
A First-In-Class, Broad-Spectrum Antiviral Agent Intending To Revolutionize Treatment of Viral Infections Including RSV, COVID, Influenzas and More
NanoViricides, Inc. elaborates on its groundbreaking host-mimetic, broad-spectrum antiviral technology platform, NV-387, designed to revolutionize viral infection treatment with advanced decoy mechanisms
![Accesswire](/assets/images/accesswire-inline.png)
-
Southern Energy Corp. Announces Payment of Interest in-Kind to its 8% Convertible Unsecured Subordinated Debentures
-
APWG 2024 Cybercrime Research Conference Extends Submission Deadline to July 7
-
Product Creation Studio Partners With PatchClamp Medtech Inc. to Develop Revolutionary Dural Repair System
-
XS Financial Enters Into Definitive Agreement to Be Taken Private
-
TRU Engages Investor Relations Specialists HE Capital Markets
![EQS Group](/assets/images/eqs-group.png)
-
Successful first half of 2024 for CQ Investment Group
-
clearvise AG realizes two more solar parks through cooperation in Italy
-
DEFENCE’S ARM-X ANTI-CANCER VACCINE INHIBITS GROWTH OF PRE-ESTABLISHED OVARIAN CANCER RESULTING IN COMPLETE RESPONSES IN TREATED ANIMALS
-
Agreement reached with iBusiness Funding to acquire Funding Circle’s US business
-
Cairn Homes Plc: Transaction in Own Shares
![Les Echos](/assets/images/les-echos.png)
-
Cie du Bois Sauvage: Buy back of own shares – week from 17/06/2024 to 21/06/2024
-
Signing of the share purchase agreement for the acquisition of a majority stake in Neoen by Brookfield from Impala and other shareholders and of a tender agreement between Brookfield and Bpifrance
-
Schneider Electric launches an offering of bonds convertible into new shares and/or exchangeable for existing shares (OCEANEs) due 2031 for a nominal amount of €750 million and a concurrent repurchase of its outstanding OCEANEs due 2026
-
Gimv increases its stake in TINC – Gimv and Belfius conclude agreement in principle on the sale of the shares of Belfius Insurance in TINC
-
Disclosure of Share Capital and Voting Rights Outstanding as of May 31, 2024